The Metastatic Risk of Renal Cell Carcinoma by Primary Tumor Size and Subtype

• Published in: European urology open science (Online) Vol. 52; pp. 137 - 144
• Main Authors: Monda, Steven M., Lui, Hansen T., Pratsinis, Manolis A., Chandrasekar, Thenappan, Evans, Christopher P., Dall'Era, Marc A.
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01.06.2023; Elsevier
• Subjects: Active surveillance; Epidemiology and End Results; Histology; Kidney Cancer; Renal cell carcinoma; Renal mass biopsy; Surveillance; Epidemiology and End Results; Renal mass biopsy; Histology; Active surveillance; Surveillance; Renal cell carcinoma
• ISSN: 2666-1683; 2666-1691; 2666-1683
• DOI: 10.1016/j.euros.2023.04.015

The likelihood of a renal mass being metastatic increases significantly with size but also varies widely with histologic subtype. Examining cancer registry data, we report a higher likelihood of metastatic renal cell carcinoma across all tumor sizes compared with what has been reported previously. Current data on the association between tumor size, subtype, and metastases, and thresholds for intervention, for renal cell carcinoma (RCC), are largely based on single-center nephrectomy registries that may under-represent those presenting with metastatic disease. We sought to assess tumor size and histologic subtype in relation to metastatic status at presentation for patients with RCC. Using Surveillance, Epidemiology and End Results cancer registry data, we identified patients with a diagnosis of RCC made between 2004 and 2019, and a known size of primary tumor. We used nodal and metastatic TNM staging to assess metastatic disease at presentation. We report the proportion of metastatic disease across varying tumor sizes for clear cell (ccRCC), papillary (pRCC), and chromophobe (chRCC) RCC. We also examine sarcomatoid RCC and RCC with sarcomatoid features (sarcRCC). Logistic regression models were used to model the likelihood of metastatic disease for each histologic subtype. Of 181096 RCC patients included, 23829 had metastatic disease. For any RCC, metastatic rates of 3.6%, 13.1%, 30.3%, and 45.1% were observed for tumors ≤4, 4–≤7, 7–≤10, and >10 cm, respectively. Metastatic rates of chRCC were low at even large sizes, 11.0% at >10 cm. In contrast, sarcRCC had high metastatic rates at all sizes, 27.1% at ≤4 cm. Metastatic rates for ccRCC and pRCC increased steadily above 3 cm. For any RCC and each evaluated subtype, tumor size was found to be associated with metastatic disease on logistic regression (p < 0.001). The likelihood of a renal mass being metastatic varies greatly with both its subtype and size. We report higher likelihoods of metastatic disease across tumor sizes compared with what has been reported previously. These results may help clinicians pick appropriate thresholds for intervention and candidates for active surveillance. We find that the metastatic probability of renal cell carcinoma varies greatly with subtype and increases with tumor size.